The anti-melanoma efficiency of the intratumoral injection of cucurbitacin-loaded sustained-release carriers: A PLGA particle system

Journal of Pharmaceutical Sciences

Volumn 102, Issue 8, 2013, Pages 2550-2563

  Jianbo, Guo ^a   Xue, Li ^a,b   Hongdan, Yu ^a   Zhaohui, Tang ^b   Xing, Tang ^a   Chenchen, Cai ^a   Jinghua, Xu ^a   Hui, Xu ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

Author keywords

Anti melanoma efficiency; Cucurbitacin; Cytotoxicity; Injectables; Intratumoral; Microparticles; Particle sizing; Pharmacokinetics; Poly(lactic glycolic) acid (PLGA); Release patterns

Indexed keywords

CUCURBITACIN; NANOPARTICLE; POLYGLACTIN;

ANIMAL CELL; ARTICLE; BIOLOGICAL ACTIVITY; CANCER INHIBITION; CELL CYCLE; CELL INTERACTION; CELL LEVEL; CYTOMETRY; CYTOTOXICITY; DRUG CONCENTRATION; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; SLOW DRUG RELEASE; SUSTAINED DRUG RELEASE;

EID: 84881030274     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23604     Document Type: Article

References (45)

1. Heldin C, Rubin K, Pietras K. 2004. High interstitial fluid pressure-An obstacle in cancer therapy. Nat Rev Cancer 4:806-813.
2. Rob C, Ioanna P, Nicholas D. 2006. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 4(2):61-70.
3. Nsereko S, Amiji M. 2002. Localized delivery of paclitaxel in solid tumors from biodegradable chitin-microparticle formulations. Biomaterials 23:2723-2731.
4. Vegt P, Debruyne F, van der Meijden AP. 1995. Bacillus calmette guerin in superficial bladder cancer: Consensus and controversies. Eur Urol. 27(2):89-95.
5. Walter KA, Tamargo RJ, Olivi A, Burger PC, Brem H. 1995. Intratumoral chemotherapy. Neurosurgery 37(6):1128-1145.
6. Haroun R, Brem H. 2000. Local drug delivery. Curr Opin Oncol. 12(3):187-193.
7. Park E, Maniar M, Shah J. 1998. Biodegradable polyanhydride devices of cefazolin sodium, bupivacaine, and taxol for local drug delivery: preparation, and kinetics and mechanism of in vitro release. J Control Release 52:179-189.
8. Walter KA, Cahan MA, Gur A, Tyler B, Hilton J, Colvin OM, Burger PC, Domb A, Brem H. 1994. Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res 54(15):2207-2212.
9. Hwang TL, Lee WR, Hua SC, Fang JY. 2007. Cisplatin encapsulated in phosphatidylethanolamine liposomes enhances the in vitro cytotoxicity and in vivo intratumor drug accumulation against melanomas. J Dermatol Sci 46:11-20.
10. Mizuguchi H, Nakanishi T, Nakanishi M, Nakagawa T, Nakagawa S, Mayumi T. 1996. Intratumor administration of fusogenic liposomes containing fragment A of diphtheria toxin suppresses tumor growth. Cancer Lett. 100:63-69.
11. Yang Y, Wang J, Zhang X, Lu W, Zhang Q. 2009. A novel mixed micelle gel with thermo-sensitive property for the local delivery of docetaxel. J Control Release 135:175-182.
12. Wolinsky J, Colson Y, Grinstaff M. 2012. Local drug delivery strategies for cancer treatment: Gels, nanoparticles, polymeric films, rods, and wafers. J Control Release 159:14-26.
13. Chakravarthi SS, De S, Miller DW, Robinson DH. 2010. Comparison of anti-tumor efficacy of paclitaxel delivered in nano- and microparticles. Int J Pharm 383:37-44.
14. Kluza E, Yeo SY, Schmid S, van der Schaft DW, Boekhoven RW, Schiffelers RM, Storm G, Strijkers GJ, Nicolay K. 2011. Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity. J Control Release 151:10-17.
15. Fujita T, Furuhata M, Hattori Y, Kawakami H, Toma K, Maitani Y. 2008. High gene delivery in tumor by intratumoral injection of tetraarginine-PEG lipid-coated protamine/DNA. J. Control Release 129:124-127.
16. Harivardhan Reddy L, Sharma RK, Chuttani K, Mishra AK, Murthy RS. 2005. Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. J Control Release 105:185-198.
17. Bao A, Phillips WT, Goins B, Zheng X, Sabour S, Natarajan M, Ross Woolley F, Zavaleta C, Otto RA. 2006. Potential use of drug carried-liposomes for cancer therapy via direct intratumoral injection. Int J Pharm 316:162-169.
18. Farahidah M, Christopher F. 2008. Engineering biodegradable polyester particles with specific drug targeting and drug release properties. J Pharm Sci 97:71-87.
19. Chakravarthi SS, Robinson DH. 2011. Enhanced cellular association of paclitaxel delivered in chitosan-PLGA particles. Int J Pharm 409:111-120.
20. De S, Miller DW, Robinson DH. 2005. Effect of particle size of nanospheres and microspheres on the cellular association and cytotoxicity of paclitaxel in 4T1 Cells. Pharm Res 22:766-775.
21. Jerant A, Johnson J, Sheridan C, Timothy JC. 2000. Early detection and treatment of skin cancer. Am Fam Physician 62(2):357-382.
22. Clark GS, Pappas-Politis EC, Cherpelis BS, Messina JL, Möller MG, Cruse CW, Glass LF. 2008. Surgical management of melanoma in situ on chronically sun-damaged skin. Cancer Control 15(3):216-224.
23. Danson S, Lorigan P. 2005. Improving outcomes in advanced malignant melanoma: update on systemic therapy. Drugs 65(6):733-743.
24. Bhatia S, Tykodi SS, Thompson JA. 2009. Treatment of metastatic melanoma: An Overview. Oncology 23(6):488-496.
25. Goldberg EP, Hadba AR, Almond BA, Marotta JS. 2002. Intratumoral cancer chemotherapy and immunotherapy: Opportunities for non systemic preoperative drug delivery. J Pharm Pharmacol. 54(2):159-180.
26. Abdullah AA. 2013. Cucurbitacins-a promising target for cancer therapy. Int J Health Sci 7:77-89.
27. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. 2003. Discovery of JSI-124 (Cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 63:1270-1279.
28. Wakimoto N, Yin D, O'Kelly J, Haritunians T, Karlan B, Said J, Xing H, Koeffler HP. 2008. Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo. Cancer Sci 99:1793-1797.
29. Yin D, Wakimoto N, Xing H, Lu D, Huynh T, Wang X, Black KL, Koeffler HP. 2008. Cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multiforme. Int J Cancer 123:1364-1375.
30. Haritunians T, Gueller S, Zhang L, Badr R, Yin D, Xing H, Fung MC, Koeffler HP. 2008. Cucurbitacin B induces differentiation, cell cycle arrest, and actin cytoskeletal alterations in myeloid leukemia cells. Leuk Res 32:1366-1373.
31. Oh H, Mun YJ, Im SJ, Lee SY, Song HJ, Lee HS, Woo WH. 2002. Cucurbitacins from Trichosanthes kirilowii as the inhibitory components on tyrosinase activity and melanin synthesis of B16/F10 melanoma cells. Planta Med 68:832-833.
32. Zhang Y, Ouyang D, Xu L, Ji Y, Zha Q, Cai J, He X. 2011. Cucurbitacin B induces rapid depletion of the G-actin pool through reactive oxygen species-dependent actin aggregation in melanoma cells. Acta Biochim Biophys Sin 43:556-567.
33. Wang JW, Zhou XM, Cao YL, Xiao JF, Ma EL, Deng YH, Chen DW. 2007. The antitumor activities of Cucurbitacin liposome for injection both in vitro and in vivo. Asia J Tradition Med 2:98-103.
34. Molavi O, Ma Z, Mahmud A, Alshamsan A, Samuel J, Lai R, Kwon GS, Lavasanifar A. 2008. Polymeric micelles for the solubilization and delivery of STAT3 inhibitor Cucurbitacins in solid tumors. Int J Pharm 347:118-127.
35. Klose D, Siepmann F, Willart JF, Descamps M, Siepmann J. 2010. Drug release from PLGA-based microparticles: Effects of the "microparticle: bulk fluid" ratio. Int J Pharm 383:123-131.
36. Avinash B, Steven JS, Karen IW. 2008. Controlling the in vitro release profiles for a system of haloperidol-loaded PLGA nanoparticles. Int J Pharm 346:151-159.
37. MTT cell proliferation assay, ATCC. Accessed at March 2002, at: www.atcc.org.
38. Devalapally H, Duan Z, Seiden MV, Amiji MM. 2007. Paclitaxel and ceramide coadministration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int J Cancer 121:1830-1838.
39. Farokhzad OC, Lange R. 2009. Impact of nanotechnology on drug delivery. ACS Nano 3:16-20.
40. Mainardes RM, Evangelista RC. 2005. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm 290:137-144.
41. Yallapu MM, Gupta BK, Jaggi M. 2010. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci 351:19-29.
42. Conner SD, Schmid SL. 2003. Regulated portals of entry into the cell. Nature 422:37-44.
43. Bacso Z, Everson RB, Eliason JF. 2000. The DNA of annexin V-binding apoptotic cell is highly fragmented. Cancer Res 60:4623-4628.
44. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. 1999. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51:691-743.
45. 188Re] rhenium sulfide suspension for treatment of transplanted human liver carcinoma in nude mice. Nucl Med Biol 27:347-352.